Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance upgrade on Thursday 4th of May 2017 from 8.00am to 9.00am (BST).

During this time our websites will be offline temporarily. If you have any questions please use the feedback button on this page. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 3, 2017
Previous Article Next Article

A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics

Author affiliations

Abstract

Cell wall biosynthesis inhibitors (CBIs) have historically been one of the most effective classes of antibiotics. They are the most extensively used class of antibiotics and their importance is exemplified by the β-lactams and glycopeptide antibiotics. However, this class of antibiotics has not received impunity from resistance development. In the wake of this predicament, this review presents the progress of CBIs, especially glycopeptide derivatives as antibiotics to confront antibacterial resistance. The various strategies used for the development of CBIs, their clinical status and possible directions in which this field can evolve have also been discussed.

Graphical abstract: A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics

Back to tab navigation
Please wait while Download options loads

Publication details

The article was received on 21 Oct 2016, accepted on 18 Jan 2017 and first published on 26 Jan 2017


Article type: Review Article
DOI: 10.1039/C6MD00585C
Citation: Med. Chem. Commun., 2017,8, 516-533
  •   Request permissions

    A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics

    P. Sarkar, V. Yarlagadda, C. Ghosh and J. Haldar, Med. Chem. Commun., 2017, 8, 516
    DOI: 10.1039/C6MD00585C

Search articles by author